Opinion

Video

Episode 1: Advancing Patient Care in Non–Muscle-Invasive Bladder Cancer

Author(s):

Max Kates, MD

A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in patient care while highlighting recent treatment advances that offer promising solutions.

Current Time 0:00
Duration 3:36
Loaded: 4.56%
Stream Type LIVE
Remaining Time 3:36
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Study data point to gender disparities in oncology research citations
    Study data point to gender disparities in oncology research citations
    Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
    Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
    1 expert in this video
    BPH Management: Patient Outcome Evolution
    Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
    Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
    Final Thoughts and Clinical Trials in NMIBC
    Final Thoughts and Clinical Trials in NMIBC
    Uptake of New Treatments in Urology Practice
    Uptake of New Treatments in Urology Practice
    Patient Communication and Treatment Adherence in NMIBC
    Patient Communication and Treatment Adherence in NMIBC
    Urinary bladder | Image Credit: © magicmine - stock.adobe.com
    Expert describes implications of neoadjuvant durvalumab approval in MIBC
    Sima Porten, MD, on gene-environment interactions in bladder cancer development
    Sima Porten, MD, on gene-environment interactions in bladder cancer development
    1 expert in this video
    Resective Surgery and Minimally Invasive Procedures For BPH
    Related Content
    Human Body Organs (Urinary Bladder) | Image Credit: @ magicmine - stock.adobe.com
    April 21st 2025

    Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan

    Hannah Clarke
    Treatment with nadofaragene led to a complete response rate of 75% at 3 months.
    Introducing Pearls & Perspectives, with Amy Pearlman, MD!
    April 21st 2025

    Introducing Pearls & Perspectives, with Amy Pearlman, MD!

    Amy M. Pearlman, MD
    Pearls & Perspectives, hosted by Amy Pearlman, MD, is the latest multimedia program from Urology Times.
    3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
    April 17th 2025

    NMIBC Clinical Forums highlight novel therapies and treatment strategies

    Urology Times staff
    Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.
    Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
    March 3rd 2025

    Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

    Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
    Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
    FDA approval sought for Anktiva in papillary NMIBC
    April 15th 2025

    FDA approval sought for Anktiva in papillary NMIBC

    Hannah Clarke
    The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.
    What urologists can expect in Q2 of 2025
    April 7th 2025

    What urologists can expect in Q2 of 2025

    Hannah Clarke Benjamin P. Saylor
    A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
    © 2025 MJH Life Sciences

    All rights reserved.